Solvonis Therapeutics PLC (LSE:SVNS) non-executive director-elect Dr Renata Crome talked with Proactive about her appointment to the board and what she brings to the company. Dr Crome has an extensive background in pharmaceutical development, having worked at Roche for 30 years. She played a key role in the development of blockbuster treatments such as bevacizumab and obinutuzumab for cancer, as well as Tamiflu for influenza. Following her time at Roche, she transitioned to board roles across commercial and charity organisations and also lectures in pharmaceutical medicine. Discussing her contributions to Solvonis, Dr Crome highlighted her strategic expertise and experience in central nervous system (CNS) treatments. "I have extensive experience in developing treatments in the central nervous system area, and I know the challenges and some of the solutions," she said. She also emphasised her ability to leverage a strong network of experts to support the company's goals. Dr Crome expressed enthusiasm for Solvonis' innovative pipeline and differentiated treatments, as well as the strength of its leadership team. "It’s a privilege to be invited to join them," she said. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future content. #SolvonisTherapeutics #Pharmaceuticals #Biotech #HealthcareInnovation #Leadership #CNSResearch #DrugDevelopment #Investing #Biopharma #ExecutiveLeadership